Neovacs SA (ALNEV) Stock Statistics & Valuation Metrics

Neovacs SA has a market cap or net worth of €476.63K. The enterprise value is €783.58M.

Neovacs SA has 476,625 shares outstanding. The number of shares has decreased by -2.65% in one year.

Neovacs SA’s return on equity (ROE) is -1.82 and return on invested capital (ROIC) is -35.84%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Neovacs SA had revenue of 366.35K and earned -32.91M in profits. Earnings per share was -188.61.

In the last 12 months, operating cash flow was -3.60M and capital expenditures -79.71K, giving a free cash flow of -3.68M billion.

Neovacs SA pays an annual dividend of ―, resulting in a dividend yield of ―

Neovacs SA upcoming earnings date is Oct 23, 2025, Before Open (Confirmed).

Neovacs SA as a current ratio of 0.63, with Debt / Equity ratio of 1.28%

In the past 12 months, Neovacs SA has paid -1.03M in taxes.

Neovacs SA EV to EBITDA ratio is -6.80, with an EV/FCF ratio of -48.30.

Neovacs SA has €435.45K in cash and marketable securities with €230.37K in debt, giving a net cash position of -€205.08K billion.

Gross margin is -2105.40%, with operating margin of -1846.44%, and net profit margin of -8984.51%.

The average price target for Neovacs SA is ―, which is 11.43% higher than the current price. The consensus rating is ―